Abstract 467P
Background
To investigate the application effect of evidence-based concept of cluster management model in oncology nutrition case management.
Methods
Experimental observation was conducted on 60 cases of oncology patients, and the study period was from August 2021 to August 2022. In the process of nutritional case management of the patients, 30 cases were included in the observation group to carry out the evidence-based concept of the cluster management mode; the other 30 patients belonged to the control group and received routine nursing guidance. Observe and compare the nutritional status and nursing satisfaction of the two groups of patients.
Results
Before nursing care, the nutritional status (S-Amy (blood amylase), U-Amy (urine amylase), Alb (serum albumin), etc.) of the patients in the two groups was assessed, and no significant difference existed between the observation group and the control group (P > 0.05); after the implementation of different nursing care measures, the nutritional status of the patients in the two groups was compared again and found to be significantly different, and that the nutritional status of the patients in the observation group was significantly better ( P<0.05). The results of patients' satisfaction with nursing interventions showed that the observation group (96.7%) was significantly higher than the control group (70.0%), with a significant difference (P < 0.05).
Conclusions
In the nutritional case management of oncology patients, the implementation of the evidence-based concept of cluster management mode can significantly improve the nutritional status of patients, help patients to strengthen their physical fitness, which is beneficial to the control of patients' conditions, and the patients' satisfaction with nursing care is high, which is worthy of promotion.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract